Tango reports 82% tumor response rate in trial of combo therapy (Daraxonrasib plus vopimetostat) for advanced #PancreaticCancer at #ESMO26
https://www.statnews.com/2026/10/23/esmo-2026-trial-results-tango-therapeutics-vopimetostat-revolution-medicines-rasonque/
Reduced toxicity data is particularly important as a lower Daraxonrasib dose can be used.
8037 views · 96 likes · 39 reposts · 5 replies
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.org- Lang Yang, MD@ynglng313674
@Aiims1742 At fixed daraxonrasib 100 mg, increasing vopimetostat from 200 to 250 mg yielded 3 DLTs in 2/4 patients. That makes dose central to the crosstalk hypothesis: tolerability at one dose does not yet show PRMT5-mediated protection of normal tissue.
- Nicholas Hornstein@GIMedOnc
@ElMonoGran42994 @Aiims1742 @BiotechCH This is why i don’t invest. The market is wrong.
- Dr. Paul De Santis, PharmD@DrPaulyDeSantis
@Aiims1742 Was PFS or any landmark OS released @grok
- El Mono Grande@ElMonoGran42994
@Aiims1742 @BiotechCH Market not impressed….apparently
- Anirban Maitra@Aiims1742
Mechanism wise there has got to be a bi-directional crosstalk between wild type RAS and PRMT5 First Daraxonrasib has greater ORR than Zoldonrasib per press release, and second: “and partly because targeting PRMT5 may attenuate some of Rasonque’s toxicities”
Source: Anirban Maitra · x.com